The current first-line treatment for peripheral T-cell lymphoma (PTCL) has a typically poor prognosis. Developing a new regimen is urgently needed. This phase I study evaluated the maximum tolerated ...

When facing a lymphoma diagnosis, understanding the available treatment options becomes crucial for patients navigating this challenging journey. Lymphoma, a cancer affecting the immune system’s ...

B-ALL/NHL 2002 protocol achieved a 3-year overall survival and progression-free survival of 73% in adult patients with Burkitt lymphoma/leukemia (BL). While demonstrating efficacy comparable with ...

This latter question was a noninferiority design that aimed to preserve a similar rate of bone marrow (BM) relapse. The trial recruited children and young adults with Philadelphia-negative ALL and ...

Memo del Bosque was diagnosed with Hodgkin’s lymphoma in 2017. This aggressive cancer primarily affects white blood cells Mexican television mourns the death of Guillermo “Memo” del Bosque ...

These findings suggest this unique cell therapy approach has promise for specific patients with lymphoma, but it may be adapted for more cancer types in the future. "We observed rapid and strong ...

Although usually identified early, skin lymphomas can be mistaken for other skin conditions, delaying diagnosis. Non-Hodgkin's lymphoma (NHL) occurs when lymphocytes called T cells and B cells become ...

Advancing care for stage 3 or 4 Hodgkin lymphoma patients The National Institute for Health and Care Excellence (NICE) has recommended brentuximab vedotin combined with doxorubicin, vinblastine and ...

Follicular lymphoma is an indolent malignancy with a generally favorable prognosis, with survival often measured in decades. Yet up to 20% of patients develop early progression after starting ...

Follicular lymphoma -- typically a slow-growing or indolent form of non-Hodgkin lymphoma that arises from B lymphocytes -- accounts for 20% to 30% of all non-Hodgkin lymphoma cases. The indolent ...

From today, adults with advanced Hodgkin lymphoma have access to a new treatment, after we recommended brentuximab vedotin (brand name Adcetris) in combination with other therapies for routine NHS use ...